[go: up one dir, main page]

CY1122929T1 - Πρωτεϊνες συγχωνευσης - Google Patents

Πρωτεϊνες συγχωνευσης

Info

Publication number
CY1122929T1
CY1122929T1 CY20201100239T CY201100239T CY1122929T1 CY 1122929 T1 CY1122929 T1 CY 1122929T1 CY 20201100239 T CY20201100239 T CY 20201100239T CY 201100239 T CY201100239 T CY 201100239T CY 1122929 T1 CY1122929 T1 CY 1122929T1
Authority
CY
Cyprus
Prior art keywords
fusion proteins
present
time
prolonged
diabetes
Prior art date
Application number
CY20201100239T
Other languages
English (en)
Inventor
David Bruce BALDWIN
John Michael Beals
Craig Duane Dickinson
Andrew Ihor Korytko
Gregory Alan Lazar
Jonathan Wesley DAY
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122929(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1122929T1 publication Critical patent/CY1122929T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε πρωτεΐνες συγχώνευσης που περιλαμβάνουν έναν αγωνιστή υποδοχέα ινσουλίνης συγχωνευμένο σε μία ανθρώπινη περιοχή IgG Fc μέσω της χρήσης ενός πεπτιδικού συνδετήρα, και στη χρήση αυτών των πρωτεϊνών συγχώνευσης στην αγωγή του διαβήτη. Η πρωτεΐνη συγχώνευσης της παρούσας εφεύρεσης έχει προφίλ παρατεταμένου χρόνου δράσης και είναι χρήσιμη για την παροχή ελέγχου βασικής γλυκόζης επί παρατεταμένη χρονική περίοδο.
CY20201100239T 2015-05-07 2020-03-16 Πρωτεϊνες συγχωνευσης CY1122929T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (1)

Publication Number Publication Date
CY1122929T1 true CY1122929T1 (el) 2021-10-29

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100239T CY1122929T1 (el) 2015-05-07 2020-03-16 Πρωτεϊνες συγχωνευσης

Country Status (42)

Country Link
US (5) US9855318B2 (el)
EP (1) EP3292141B1 (el)
JP (1) JP6591562B2 (el)
KR (1) KR102059736B1 (el)
CN (1) CN107531806B (el)
AR (1) AR105616A1 (el)
AU (1) AU2016257659B2 (el)
BR (1) BR112017020502A2 (el)
CA (1) CA2981102A1 (el)
CL (1) CL2017002761A1 (el)
CO (1) CO2017011301A2 (el)
CR (1) CR20170469A (el)
CY (1) CY1122929T1 (el)
DK (1) DK3292141T3 (el)
DO (1) DOP2017000258A (el)
EA (1) EA039770B1 (el)
EC (1) ECSP17073650A (el)
ES (1) ES2799099T3 (el)
HK (1) HK1244019A1 (el)
HR (1) HRP20200503T1 (el)
IL (1) IL254965B (el)
JO (1) JO3658B1 (el)
LT (1) LT3292141T (el)
MA (1) MA42037B1 (el)
MD (1) MD3292141T2 (el)
ME (1) ME03709B (el)
MX (1) MX2017014284A (el)
MY (1) MY183025A (el)
NZ (1) NZ736470A (el)
PE (1) PE20180507A1 (el)
PH (1) PH12017502025A1 (el)
PL (1) PL3292141T3 (el)
PT (1) PT3292141T (el)
RS (1) RS60044B1 (el)
SG (1) SG11201708194WA (el)
SI (1) SI3292141T1 (el)
SV (1) SV2017005548A (el)
TN (1) TN2018000059A1 (el)
TW (1) TWI656132B (el)
UA (1) UA122146C2 (el)
WO (1) WO2016178905A1 (el)
ZA (1) ZA201706334B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
BR112019000968A2 (pt) 2016-07-27 2019-04-30 Hewlett-Packard Development Company, L.P. interface horizontal para cartucho de suprimento de fluido tendo sensor de nível de fluido digital
LT3551209T (lt) 2016-12-09 2021-09-10 Akston Biosciences Corporation Insulino-fc suliejimai ir panaudojimo būdai
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
MA49339A (fr) * 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
AU2019212703A1 (en) 2018-01-26 2020-08-13 Genentech, Inc. Compositions and methods of use
AU2019295637B2 (en) 2018-06-25 2022-12-22 The Board Of Trustees Of The Leland Stanford Junior University De novo design of potent and selective interleukin mimetics
US11267862B2 (en) * 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HRP20230991T1 (hr) * 2018-06-29 2023-12-08 Akston Biosciences Corporation Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe
EP3863680A1 (en) 2018-10-10 2021-08-18 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
CA3119472A1 (en) 2018-11-20 2020-05-28 University Of Washington Split interleukin mimetics and their use
CA3128522C (en) * 2019-03-15 2024-04-02 Eli Lilly And Company Preserved formulations
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
LT4073098T (lt) 2019-12-19 2023-12-11 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir jų naudojimo būdai
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides
KR20220164736A (ko) 2020-04-07 2022-12-13 네오레우킨 테라퓨틱스, 인코포레이티드 안지오텐신 전환 효소 2(ace2)의 드노보 단백질 디코이
CA3146464C (en) 2020-04-10 2024-03-12 Todd C. Zion Antigen specific immunotherapy employing covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2022017309A1 (zh) * 2020-07-24 2022-01-27 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
EP4259185A1 (en) 2020-12-14 2023-10-18 Eli Lilly and Company Methods of treating diabetes
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
AU2023236225A1 (en) * 2022-03-16 2024-09-26 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Human insulin analogue, and fusion protein thereof and medical use thereof
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
TW202417519A (zh) 2022-06-23 2024-05-01 法商賽諾菲公司 單鏈胰島素及其Fc接合物
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
WO2024229093A1 (en) 2023-05-03 2024-11-07 Eli Lilly And Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
CA2468100A1 (en) 2001-12-20 2003-07-03 Eli Lilly And Company Insulin molecule having protracted time action
CN101974090B (zh) * 2003-06-12 2015-06-17 伊莱利利公司 Glp-1类似物融合蛋白质
AU2003296244A1 (en) 2003-10-02 2005-05-11 Carl Zeiss Smt Ag Optical subassembly and projection objective for semiconductor lithography
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
CN105131127B (zh) * 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
CA2691695C (en) 2007-07-10 2014-03-18 Eli Lilly And Company Glp-1-fc fusion protein formulation
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032287T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US20110195896A1 (en) 2008-04-22 2011-08-11 Case Western Reserve University Isoform-specific insulin analogues
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
AU2009274738B2 (en) 2008-07-23 2012-12-13 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US10286037B2 (en) 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
SG11201503522RA (en) 2012-11-05 2015-06-29 Univ Case Western Reserve Long-acting single-chain insulin analogues
PT2963055T (pt) 2013-02-26 2019-07-25 Hanmi Pharm Ind Co Ltd Conugado de insulina específico ao local
EA201591700A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
CA2937168A1 (en) 2014-01-20 2015-07-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
EP3204410B1 (en) 2014-10-06 2021-01-20 Case Western Reserve University Biphasic single-chain insulin analogues
SG10201809427SA (en) 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
RS60044B1 (sr) 2020-04-30
PH12017502025B1 (en) 2018-04-02
CN107531806A (zh) 2018-01-02
MY183025A (en) 2021-02-07
US20180177851A1 (en) 2018-06-28
AR105616A1 (es) 2017-10-25
PT3292141T (pt) 2020-04-22
US9855318B2 (en) 2018-01-02
SI3292141T1 (sl) 2020-04-30
US20160324932A1 (en) 2016-11-10
WO2016178905A1 (en) 2016-11-10
ME03709B (me) 2021-01-20
US11253574B2 (en) 2022-02-22
CL2017002761A1 (es) 2018-05-18
AU2016257659A1 (en) 2017-10-12
CR20170469A (es) 2017-11-14
PE20180507A1 (es) 2018-03-09
US20200390865A1 (en) 2020-12-17
KR20170134614A (ko) 2017-12-06
TW201712029A (zh) 2017-04-01
ECSP17073650A (es) 2018-02-28
US12059452B2 (en) 2024-08-13
SV2017005548A (es) 2018-04-24
KR102059736B1 (ko) 2019-12-26
NZ736470A (en) 2019-04-26
EA039770B1 (ru) 2022-03-11
CA2981102A1 (en) 2016-11-10
DOP2017000258A (es) 2017-12-31
AU2016257659B2 (en) 2018-08-09
ZA201706334B (en) 2020-01-29
JO3658B1 (ar) 2020-08-27
LT3292141T (lt) 2020-03-25
SG11201708194WA (en) 2017-11-29
EA201792199A1 (ru) 2018-03-30
DK3292141T3 (da) 2020-04-20
PL3292141T3 (pl) 2020-06-29
PH12017502025A1 (en) 2018-04-02
HK1244019A1 (zh) 2018-07-27
US10709766B2 (en) 2020-07-14
CO2017011301A2 (es) 2018-03-20
UA122146C2 (uk) 2020-09-25
JP2018515088A (ja) 2018-06-14
ES2799099T3 (es) 2020-12-14
BR112017020502A2 (pt) 2018-07-03
MA42037B1 (fr) 2020-03-31
US20250032588A1 (en) 2025-01-30
MX2017014284A (es) 2018-03-23
HRP20200503T1 (hr) 2020-06-26
IL254965A0 (en) 2017-12-31
EP3292141B1 (en) 2020-02-12
IL254965B (en) 2021-03-25
US20220211818A1 (en) 2022-07-07
JP6591562B2 (ja) 2019-10-16
EP3292141A1 (en) 2018-03-14
CN107531806B (zh) 2022-06-07
TWI656132B (zh) 2019-04-11
MD3292141T2 (ro) 2020-07-31
TN2018000059A1 (en) 2019-07-08

Similar Documents

Publication Publication Date Title
CY1122929T1 (el) Πρωτεϊνες συγχωνευσης
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1122539T1 (el) Αναλογα γλυκαγονης
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
EA201790213A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
CO2018008558A2 (es) Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
EP3765489C0 (en) THERAPEUTIC COMBINATION OF 4-1BB AGONISTS AND ANTIBODIES AGAINST CD20
CY1120281T1 (el) Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail
CO2018007582A2 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
AR106144A1 (es) Un conjugado de proteína que comprende polipéptidos fisiológicos y una región fc inmunoglobulina
MX360295B (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
IL276616A (en) Dosage for treatment with IL-22 Fc fusion proteins
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
EA201991340A1 (ru) Способы индуцирования иммунологической толерантности к факторам свертывания крови
EA202090582A2 (ru) ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
AR095528A1 (es) Polipéptidos de interleucina-22 (il-22) y proteínas de fusión de il-22 con fragmento de cadena pesada fc (il-22 fc) y métodos de uso
TH177202A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้